New drug combo tested for Tough-to-Treat blood cancer
NCT ID NCT03844815
Summary
This early-stage study is testing the safety of combining two drugs, venetoclax and decitabine, for adults with high-risk acute myeloid leukemia (AML). The main goal is to find the highest dose patients can tolerate without severe side effects. It is for patients whose cancer has returned, didn't respond to treatment, or has specific genetic features that make it harder to treat.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.